Completed COVID/Post-COVID Trials
PB1046-PT-CL-0007 - VANGARD
A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of PB1046, a Sustained-Release VIP ANalogue, in Hospitalized COVID-19 patients at High Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)
- Enrollment Status: Terminated
- Study Type: Interventional
- PI: Leslie A. Spikes, M.D.